A study has demonstrated that the combination of PD-1 inhibitors with anti-VEGF-targeted drugs shows better therapeutic effects than monotherapy in the systemic treatment of patients with advanced HCC [8]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.